Leprosy is an infectious and contagious disease characterized by insidious development, high infectivity, and low pathogenicity, whose human transmission occurs mainly through upper airways.^[@r1]^ The etiological agent (*Mycobacterium leprae*) presents tropism on the skin and peripheral nerves and, as it multiplies slowly, the incubation period can vary from three to five years.^[@r1],[@r2]^ The later the disease is diagnosed, the greater the risk of developing deformities and disabilities.^[@r3]^

Although it mainly affects young adults, leprosy in children under 15 years of age is a strong indicator of the recent transmission index of still undiagnosed cases, suggesting a high transmissibility and early exposure to bacteria, in turn increasing the chances of secondary disabilities.^[@r3]^ Recognizing the profile of leprosy during childhood is important to finding the proper control strategies for this often neglected disease.

This research was a retrospective case series study, aimed at describing the profile of leprosy in children under 15 years of age at a reference center in the southeastern regions of Brazil. Patients were selected through the Services databank and the sample included all of the cases confirmed between 2004 and 2012. All of the cases suspected in the first consultation were submitted to the protocol, including: bacilloscopy, Mitsuda, skin biopsy, and, as of 2010, a serum dose of phenol glycopeptide-I (PGL-1). The definitions adopted in this study for the classification of the cases, disabilities, and reactions were published in a prior study.^[@r2]^ The data were analyzed by employing descriptive statistics and association tests (t-student, Wilcoxon, and χ^2^), considered significant if p\<0.05.

In the period from 2004 to 2012, 206,837 outpatient appointments (new cases and return patients) were conducted at the Reference Center; of these, 10.8% (22,405) received medical care dedicated to patients with leprosy. In children of under 15 years of age, 18 new cases of leprosy were identified during the period, with an average of 10.0 ± 3.6 years (16.6% from 0-5 years), and 55.6% of the sample, corresponding to the female gender. The median time between the first symptoms and the diagnosis was of 11 months (4-24). Home contact with leprosy was confirmed in 77% of the cases.

Upon hospital admission, 66.7% of the children under 15 years of age presented mostly skin symptoms; 33.3%, of mostly neural symptoms; while 27.8% already presented disabilities (all degree 2). The majority were classified as multibacillary (66.7%). Half of the sample developed a reaction during the follow-up period, while 22.2% developed a later disability. [Chart 1](#t1){ref-type="table"} summarizes the other clinical-laboratory characteristics.

###### 

Description of the clinical and laboratory characteristics of 18 patients under 15 years of age diagnosed with leprosy and followed up in a reference center in the southeastern regions of Brazil (2004-2012)

  Case   Main symp­toms upon hospital admission   Home contact (yes/no - who)            Bacillo­scopy (+)                  Mitsuda (mm)   PGL-1[\*](#TFN2){ref-type="table-fn"}   Sensory- motor test                                EMG[†](#TFN3){ref-type="table-fn"}        Type of reaction                       Treat­ment of reaction     Type of later dis­ability
  ------ ---------------------------------------- -------------------------------------- ---------------------------------- -------------- --------------------------------------- -------------------------------------------------- ----------------------------------------- -------------------------------------- -------------------------- --------------------------------------------------
  1      Neural                                   YES - FA­THER and MOTHER               2+                                 10.5           NO                                      Loss of protective sensibility in hands and feet   NR[‡](#TFN4){ref-type="table-fn"}         Type 1                                 Corticoid                  Loss of protective sensibility in hands and feet
  2      Neural                                   YES - FA­THER and MOTHER               N[§](#TFN5){ref-type="table-fn"}   4.5            YES                                     Loss of protective sensibility in hands and feet   Normal                                    NA[\|\|](#TFN6){ref-type="table-fn"}   NA                         NA
  3      Neural                                   NO                                     4+                                 0.0            NO                                      Loss of protective sensibility in hands            Left nail demyelin­ation                  Type 1                                 Corticoid                  Ulnar claw
  4      Skin                                     NO                                     N                                  10.0           YES                                     NR                                                 NR                                        NA                                     NA                         NA
  5      Neural                                   YES - FA­THER                          1+                                 5.0            NO                                      Normal                                             NR                                        Type 1                                 Corticoid                  NA
  6      Neural                                   YES - FA­THER                          1+                                 3.5            YES                                     Loss of protective sensibility in hands and feet   Senso­ry-motor multiple mononeu­ropathy   Type 1                                 Corticoid                  Bilateral ulnar claw and bilat­eral tibial claw
  7      Skin                                     NO                                     1+                                 5.0            YES                                     Normal                                             NR                                        NA                                     NA                         NA
  8      Skin                                     YES - FA­THER                          N                                  3.0            NO                                      NR                                                 NR                                        Type 2                                 Corticoid                  NA
  9      Skin                                     YES - FA­THER                          5+                                 0.0            YES                                     Normal                                             NR                                        Type 2                                 Thalid­omide + Corticoid   NA
  10     Skin                                     NO                                     4+                                 0.0            YES                                     Normal                                             NR                                        Type 1                                 Corticoid                  NA
  11     Skin                                     YES - TWO BROTH­ERS AND GRAND­MOTHER   N                                  6.0            YES                                     Normal                                             NR                                        NA                                     NA                         NA
  12     Neural                                   NO                                     3+                                 6.0            YES                                     Normal                                             NR                                        NA                                     NA                         NA
  13     Skin                                     NO                                     N                                  10.0           YES                                     Normal                                             NR                                        Type 1                                 Corticoid                  Lagoph­thalmos
  14     Skin                                     YES - MOTHER                           1+                                 5.0            NO                                      NR                                                 Flow change in the right ulnar nerve      Type 1                                 Corticoid                  NA
  15     Skin                                     YES -FA­THER                           N                                  0.0            NO                                      NR                                                 NR                                        NA                                     NA                         NA
  16     Skin                                     YES - MOTHER                           N                                  5.5            NO                                      NR                                                 NR                                        NA                                     NA                         NA
  17     Skin                                     NO                                     N                                  0.0            NO                                      NR                                                 NR                                        NA                                     NA                         NA
  18     Skin                                     NO                                     N                                  5.0            YES                                     NR                                                 NR                                        NA                                     NA                         NA

**Legend:**

**PGL-1=**phenol glycopeptide-I;

**EMG=**Eletroneuromiography;

**NR=**Not realized; **N**

=negative;

**NA=**Not applicable/Did not present

[Graph 1A](#f1){ref-type="fig"} illustrates the age distribution according to the diagnosis of delayed disabilities (Student t, p=0.47). In figure 1B, although the medians of time between the first symptoms and the diagnosis were not different among the patients with predominant initial skin and neural symptoms, the greater proportion of patients with neural symptoms developed a later disability (χ^2^, p=0.04).

Graph 1**A.** Distribution of age characteristics according to the diagnosis of later disabilities in 18 patients under 15 years of age with leprosy in a reference center located in the southeastern regions of Brazil (2004-2012). **B.** Distribution of the medians of time between the first symptoms and the diagnosis of leprosy in 188 patients of under 15 years of age according to the type of symptoms most commonly found in the first doctor's appointment, stratified according to the development of later disabilities.

In the same period analyzed for this study (2004-2012), the number of new cases in children under 15 years of age in Brazil fell from 4,000 new cases/year to a little over 2,300 new cases/year. As a result, the detection coefficient dropped from 7.68 to 4.88.^[@r4]^

The high proportion of disabilities within the diagnosis of these samples, when compared to previous studies, may well be due to the delay in diagnosis and to the tertiary feature of the location of this study. However, one study conducted with secondary data in Rio de Janeiro (2001-2009) also found a high proportion of disabilities within the diagnosis, with a discrete drop in the proportion of disabilities as of 2008.^[@r3],[@r5],[@r6],[@r7]^

Although the majority of cases published in India, China, and Brazil were paucibacillary, the present study found a predominance of multibacillary cases in this sample, which is in accordance with two studies reviewed by Palit & Inamadar.^[@r2],[@r3],[@r5],[@r6],[@r7],[@r8]^

Few studies evaluated the development of reactions in this age range, finding incidences of 1.36% to 29.7%, while 50% of this sample presented reactions, which can also justify the high prevalence of later disabilities found in this study.^[@r1],[@r2],[@r8],[@r9]^ Unsatisfactory results pertaining to the degree of disability in the cure of the disease were also observed by Flach *et al.*, suggesting that there is a significant proportion of patients who do not finish their leprosy treatment within the public health system in Brazil.^[@r7]^

Unlike other prior studies, nearly 80% of the investigated children confirmed home contact with leprosy.^[@r2],[@r8],[@r9]^ In recent years, heavily influenced by the results of the introduction of the Family Health Strategy in the majority of Brazilian municipalities, the averge percentage of home contact cases rose from 45.5% in 2004 to 74.5% in 2012.^[@r4]^

This study does contain limitations inherent to the methodology and profile of the location of the study, which do not, however, render these findings invalid.

The needs for community participation and the engagement of health services in tracking down suspected cases, especially in this vulnerable age range, have proven to be significant in combatting this disease, given that one does not expect children to actively seek out medical care.^[@r9]^ Health education activities in schools appear to be an important tool in the fight against this disease.^[@r7]^

Despite the efforts to reduce the incidence of leprosy in children, data suggest that, unfortunately, the targets will not be soon be met: leprosy still represents a public health problem in many countries, and reports such as this highlight the high prevalence of complications in this age range.^[@r1],[@r2],[@r10]^ Therefore, it is essential that public health policies intensify preventive measures and continue the active search for undiagnosed cases, especially at primary levels of medical care.
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